Introduction
The antiepileptic drug valproic acid readily crosses the placenta and use of the drug in pregnancy is associated with increased fetal malformation and potential toxicity (Barzago et al., 1996) . In many instances, valproic acid accumulates in higher concentrations in the fetal blood (Dickinson et al., 1979; Ishizaki et al., 1981; Nau et al., 1982; . The biochemical mechanisms mediating the rapid and disproportionate amount of valproic acid distribution across the placenta are not fully understood.
Explanations have included observations that with the progression of pregnancy a pH gradient develops across the placental barrier that influences the distribution of weak acids, including valproic acid, and weak bases across the placenta (Nau and Scott, 1986) . Maternal levels of fatty acids also rise in the circulation in pregnancy, displacing protein-bound valproic acid which is then available for transfer across the placental barrier (Nau et al., 1984; Nau, 1986 ) to a milieu with an increased availability of protein binding in the fetal serum (Froesher et al., 1984) . Finally, based on comparisons with more polar metabolites, it has been suggested that valproic acid transfer across the placenta is correlated with lipophilicity which facilitates diffusion across the trophoblast interface (Fowler et al., 1989) . Therefore, the transfer of valproic acid across the placenta has been attributed to multiple factors.
Valproic acid has been shown to be a substrate for monocarboxylic acid transporters (MCTs) in the gastrointestinal epithelium (Tsuji et al., 1994; Tamai et al., 1995; and specifically by the MCT1 isoform (Tamai et al., 1995) . Along with the considerations of pH, protein binding, and lipophilicity considerations, the existence of carrier mechanisms could play an important role determining the distribution of drugs Carrier-mediated transport of valproic acid in BeWo cells, a human trophoblast cell line. Int. J. Pharm. 195, [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] . PMID: 10675689. Publisher's official version: <http://dx.doi.org/10.1016/S0378-5173(99)00398-1> . Open Access version: http://kuscholarworks.ku.edu/dspace/.
3 and drugs of abuse across the placental barrier (Ganapathy et al., 1999) . The mRNAs for five of at least seven putative MCTs have been recently identified in the human placenta (Price et al., 1998) . In the absence of specific inhibitors, the functional significance of individual MCT isoforms in the placenta has not been established.
However, past studies with brush border membrane preparations from human trophoblasts (Balkovetz et al., 1988) and with the perfused human placental lobe (Carstensen et al., 1983) have revealed proton-dependent, carrier-mediated lactate transport that is presumed to be due to a MCT. We have also demonstrated an asymmetric, proton-dependent, carrier mediated transport of benzoic acid across BeWo cells (Utoguchi et al., 1999) , a trophoblast-like human choriocarcinoma cell line .
We have hypothesized that valproic acid might also be transported via a MCT contributing to the observed distribution of valproic acid across the placental barrier.
Therefore, to implicate or rule out the role of a MCT our objective in this study was to characterize the biochemical properties of valproic acid uptake and transport by the human trophoblast using BeWo cells. (Pattillo and Gey, 1968) . The BeWo clone (b30) was obtained from Dr. Alan Schwartz (Washington University, St. Louis, MO). The cells were cultured by the methods previously described and generally cells used in this study were from passages 28 to 40 . Briefly, the cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% heat-inactivated FBS containing 0.37% sodium bicarbonate and 1% antibiotics (10,000 U/ml penicillin and 10 mg/ml streptomycin 
Materials and Methods

Transport Experiments. A horizontal Side-Bi-Side diffusion apparatus
(Crown Glass) was used to measure the transmonolayer permeability of cells grown on the surface of 0.4 µm pored polycarbonate filters, as previously described . The cells faced the donor chamber as the apical side, and the polycarbonate membrane faced the receiver chamber as the basal side. The water jacket surrounding the donor and the receiver chambers was thermostated at 37°C. The contents of each chamber were continuously stirred at 600 rpm with magnetic stir bars. When the apicalto-basal transport studies were performed, the pH of the donor (apical) side was 6.0 and that of receptor (basal) side was 7.4. When the basal-to-apical transport studies were performed, the pH of the donor (basal) side was 6.0 and that of receptor (apical) side was 7.4. The concentration of added [ 14 C]valproic acid was 4.6 µM (0.25 µCi/ml). A 0.2-ml aliquot from the receiver chamber was taken at several time points up to 60 min.
Utoguchi, N. and Audus, K.L. (2000) Carrier-mediated transport of valproic acid in BeWo cells, a human trophoblast cell line. Int. J. Pharm. 195, [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] for the BeWo monolayers, P e , was calculated from the following relationship 1/P t = 1/P e + 1/P m Eq. (1) where Pt is apparent permeability coefficient for the collagen-coated membrane in the presence of BeWo cell monolayers, and P m is the apparent permeability coefficient for collagen-coated polycarbonate membrane alone (Adson et al., 1994 ).
2.6
Data Analysis. To estimate the values of the kinetic parameters of saturable uptake by BeWo cells, the uptake rate (J) was fitted to the following equation, which consists of both saturable and nonsaturable linear terms, using a nonlinear leastsquares regression analysis program MULTI (Yamaoka et al., 1981) :
where Jmax is the maximum uptake rate for a carrier-mediated process, C is the valproic acid concentration, K t is the half-saturation concentration (Michaelis constant), and k is a nonsaturable clearance constant.
2.7 Statistical Analysis. All results were expressed as means ± standard deviation (SD). Statistical analysis between two groups was performed using Student's t-test, and one-way analysis of variance (ANOVA) was used for single and multiple comparisons. P values of 0.05 or less were considered to indicate a statistically significant difference.
Results
Utoguchi, N. and Audus, K.L. (2000) Carrier-mediated transport of valproic acid in BeWo cells, a human trophoblast cell line. Int. J. Pharm. 195, [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] Moreover, carbonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP; 50 µM), a protonophore, significantly inhibited the uptake (Table 1) , whereas 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS; 0.1 mM), an anion-exchange inhibitor, had no inhibitory effect. These studies were carried out with concentrations of inhibitors shown to be effective in other cell systems to identify the respective protongradient and anion-exchange mechanisms (Tsuji et al., 1994) . These findings suggested that valproic acid uptake by BeWo cells is dependent on cellular energy expenditure and a proton gradient.
Specificity of the valproic acid uptake mechanism. To investigate the specificity of the carrier process involved in [ 14 C]valproic acid uptake by BeWo cells, we studied the effects of various mono-and dicarboxylic acids on this uptake. Results are presented in Table 2 . Each monocarboxylic acid tested significantly inhibited the uptake of [ 14 C]valproic acid, whereas none of the dicarboxylic acids were effective inhibitors.
These results imply that the carrier that mediates valproic acid uptake by BeWo cells is a nonspecific monocarboxylic acid carrier.
To characterize the competitive nature of the mechanism mediating uptake of valproic acid, we analyzed the inhibitory effect kinetically. Figure 4A 
Discussion
We have characterized the BeWo cell line as an in vitro system to investigate some of the transport and metabolism properties of the human trophoblast . The BeWo cell line is particularly attractive for these studies because it is stable, relatively easy to maintain by passage, and grows to a confluent monolayer in relatively short period of time. More importantly, the BeWo cell displays morphological properties and biochemical marker enzymes common to normal trophoblasts (Pattillo and Gey, 1968; Liu et al., 1997; Kenagy et al., 1998) and have been shown applicable to the characterization of asymmetric transcellular transport of serotonin and monoamine uptake (Prasad et al., 1996) , asymmetric amino acid transport (Furesz et al., 1993; Moe et al., 1994; Way et al., 1998) , asymmetric transferrin transport (Van der Ende et al., 1990; Cerneus et al., 1993) , asymmetric fatty acid transport , choline uptake (Eaton and Sooranna, 1998a) , glucose modulation of arginine transport (Eaton and Sooranna, 1998b) , and asymmetric IgG transport (Ellinger et al., 1999) . Recently, we have shown an asymmetric, proton-dependent transport of representative monocarboxylic acids, benzoic acid and acetic acid, in the BeWo cells (Utoguchi et al., 1999) .
In this study, we have been able to establish the putative role of a MCT in carriermediated transport of valproic acid in the trophoblast using the BeWo cell line.
Valproic acid uptake (or transport) by BeWo cells was saturable at higher concentrations and strongly inhibited by metabolic inhibitors, properties suggestive of an energy dependent carrier mediated process. Although valproic acid uptake by BeWo cells was not inhibited in a Na+-depleted buffer, prepared by substituting choline chloride for NaCl and NaH 2 PO 4 (data not shown), valproic acid uptake was pHdependent and the protonophore FCCP inhibited the uptake of valproic acid. These results strongly suggest that valproic acid uptake was proton-gradient-dependent. In addition, both valproic acid uptake and transport were significantly inhibited by representative monocarboxylic acids. Kinetic analysis revealed a competitive inhibition with a typical MCT substrate, benzoic acid (Tsuji et al., 1994; Tamai et al., 1995; .
Finally, the transport of valproic acid was asymmetric, favoring predominant transport in the apical to basolateral direction which corresponds to maternal to fetal distribution of the drug. Collectively, the transport properties of valproic acid were consistent with previous reports on MCT activity in intestinal epithelium (Tsuji et al., 1994; Tamai et al., Utoguchi, N. and Audus, K.L. (2000) Carrier-mediated transport of valproic acid in BeWo cells, a human trophoblast cell line. Int. J. Pharm. 195, [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] . PMID: 10675689. Publisher's official version: <http://dx.doi.org/10.1016/S0378-5173(99)00398-1> . Open Access version: http://kuscholarworks.ku.edu/dspace/.
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1995;1997), the behavior of lactate transport in trophoblast brush border membrane preparations (Balkovetz et al., 1988) , and with our earlier work on benzoic acid uptake and transport by BeWo cells (Utoguchi et al., 1999) . Therefore, we propose that valproic acid is transported across the human trophoblast by an apparent MCT and this mechanism likely plays a key role in facilitating the rapid and significant distribution of the unbound drug into the fetal compartment.
From previous literature, we noted that there were at least three factors considered important in explaining valproic acid's rapid transfer across the placenta and accumulation in the fetal compartment: the pH gradient, protein binding, and lipophilicity. Our findings are not inconsistent with the role of these factors. For instance, with the proton-dependent transport by an apparent MCT here is consistent with the observed pH-dependence of valproic acid transfer across the placenta (Nau and Scott, 1986) . Similarly, protein binding remains important. Valproic acid is greater than 90% protein bound, however, the fraction bound decreases with advancing time in pregnancy. It is only the non-protein bound valproic acid that is available for transfer across the placenta (Fowler et al., 1989) . To assess free valproic acid transport in an albumin-depleted condition, our studies were performed in the absence of serum.
Although not included here, one could consider a series of experiments where serum levels on both sides of the BeWo monolayers are manipulated to approximate protein gradients present across the placenta. We have shown in other studies that serum albumin does substantially reduce the transport of highly bound fatty acids across BeWo monolayers Shi et al., 1997) . Lastly, concerning the role of lipophilicity, valproic acid can be metabolized to a number of more hydrophilic metabolites by the liver. Some of the representative valproic acid metabolites are glucuronide conjugates which have a very poor ability to permeate across the placenta.
Because it was more lipophilic, valproic acid was proposed to cross the placenta more rapidly than the glucuronide metabolites (Fowler et al., 1989) . Considering the possible role of a MCT shown here, an alternative explanation might be the lack of affinity of the valproic acid-glucuronide conjugates for the carrier mechanism. We should note that in the perfused human placental lobe studies (Fowler et al., 1989) , recirculating valproic acid is not metabolized for up to six hours. Therefore, in our simpler and shorter timed studies with trophoblasts, the formation of valproic acid metabolites was considered unlikely and would not interfere in the transport studies.
MCT1 appears to be the predominant isoform in tissues such as the intestine and has been shown to provide a mechanism for valproic acid transport (Tsuji et al., 1994; Tamai et al., 1995; . By contrast, valproic acid uptake in the brain is believed to be mediated by a medium-chain fatty acid carrier (Adkison and Shen, 1996) and not a MCT. While BeWo cells do possess fatty acid carriers Campbell et al., 1997) , our data here clearly demonstrated that valproic acid transport can be strongly and competitively inhibited by monocarboxylic acids just as observed in the intestinal epithelium (Tamai et al., 1995) . It is possible that valproic acid can be transported differently depending on the tissue location or more likely, be transported by multiple carrier mechanisms at the placental barrier.
Monocarboxylic acids are transported out of muscle and into liver (the so-called
Cori cycle) by proton-coupled MCTs. The Cori cycle is a well-known natural physiological process (Garcia et al., 1995) . The physiological role of a MCT in the trophoblast is believed to be one of controlling the distribution of monocarboxylic acid metabolites across the placenta (Carstensen et al., 1983; Balkovetz et al. 1988 ).
Pharmacologically, a placental MCT may be implicated in facilitating monocarboxylic acid drugs (e.g., valproic acid, ibuprofen, salicylate) transfer between the maternal and fetal compartments. This would be in agreement with the proposed role of MCTs in absorption processes in the intestinal epithelium (Tsuji et al., 1994; Tamai et al., 1995; Ogihara et al., 1996) . Since, several MCT isoforms are known to exist in a variety of cell types (Price et al., 1998) , future studies will have to include identification of the specific the MCT type or types associated with the placental barrier and their respective substrate selectivity properties to fully establish their importance in pharmacology.
In summary, a putative MCT was shown to facilitate valproic acid uptake and transport across a human trophoblast monolayer. MCT-mediated transport of valproic acid represents an alternative mechanism that can be implicated in the observed ready distribution of the drug across the placental barrier. 
